Larimar Therapeutics COO receives 800K-share option

The option award vests in stages beginning September 29, 2027, subject to continued service through each applicable vesting date.

Rhea-AI Filing Summary

On September 29, 2026, Larimar Therapeutics, Inc. (LRMR) President and COO John B. Harlow Jr. received 50,000 restricted stock units, each a contingent right to one common share upon settlement, and an option to buy 800,000 common shares at $3.14 per share. The option expires September 29, 2036.

Insider Trade Summary

Grant/Award: 850,000 shares

Grant/Award 2 txns

Insider Harlow John B. Jr.

Role President and COO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F2	800,000	$0.00	$0.00
Grant/Award	Common Stock F1	50,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 800,000 contracts (Direct); Common Stock — 50,000 shares (Direct)

Footnotes (2)

1. F1. Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
2. F2. The option vests 25% on September 29, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.

Key Figures

Restricted stock units granted: 50,000 units Option shares: 800,000 common shares Exercise price: $3.14 per share +3 more

6 metrics

Restricted stock units granted 50,000 units Granted September 29, 2026; each represents a contingent right to one common share upon settlement

Option shares 800,000 common shares Option granted September 29, 2026

Exercise price $3.14 per share Option to buy common shares

Initial vesting portion 25% Vests September 29, 2027

Remaining vesting portion 75% Vests in equal monthly installments over the following 36 calendar months

Option expiration September 29, 2036 Expiration date of the option

Key Terms

restricted stock unit, contingent right, vesting

3 terms

restricted stock unit financial

"Each share is represented by a restricted stock unit"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

contingent right financial

"Each RSU represents a contingent right to receive one share"

vesting financial

"The option vests 25% on September 29, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How does the LRMR president's option award vest?

John B. Harlow Jr.'s option award vests 25% on September 29, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following that date. Vesting is subject to his continued service through each applicable vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/01/2026 - 04:27 PM Accepted by SEC EDGAR 10/01/2026 - 04:27 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Harlow John B. Jr.

(Last) (First) (Middle)

C/O LARIMAR THERAPEUTICS, INC.

THREE BALA PLAZA EAST, SUITE 506

(Street)

BALA CYNWYD PENNSYLVANIA 19004

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Larimar Therapeutics, Inc. [ LRMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and COO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/29/2026		A		50,000(1)	A	$0.00	50,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.14	09/29/2026		A		800,000		(2)	09/29/2036	Common Stock	800,000	$0.00	800,000	D

Explanation of Responses:

1. Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

2. The option vests 25% on September 29, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.

	/s/ Jennifer Johansson, Attorney-in-fact	10/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)